Use of intravenous iron and ESAs was low among patients with stage 3 to 5 CKD.
The rate of esophageal and gastric erosions among patients on dialysis eligible for anemia treatment was approximately 49 events per 100 patient-years, investigators report.
Patients receiving peritoneal dialysis rather than hemodialysis or both modalities have the lowest rate of ESA hyporesponse.
Patients with persistent ESA hyporesponse had especially high rates of adverse events.
The new tool goes beyond hemoglobin measurement to include the effects of anemia on patients’ quality of life.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
In both men and women, the prevalence of severe anemia increased as kidney function decreased.
Patients with anemia may know some of the risks associated with the condition, but do they know about potential cancer-related risks? How can health care professionals educate patients on the risks, and what is known about the potential association between newly diagnosed anemia and cancer risk?
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.